Could BPC-157 Fuel Cancer?

Free Peptide Database: https://join.bioavailable.app/ In this evidence-graded explainer, we separate three different questions that often get collapsed online: 1. Can BPC-157 initiate cancer by damaging healthy DNA? 2. Could BPC-157 promote disease that already exists? 3. Could BPC-157 support tumor blood-vessel growth through angiogenesis? The short version: there is no evidence that BPC-157 causes cancer, and no documented human cancer case attributed to it was found in this video. But there is a real unresolved promotion question, because BPC-157 does activate repair and blood-vessel pathways that are biologically relevant to tumors. Human evidence is too small, too short, and not cancer-focused enough to prove safety or danger either way. This video walks through: Cancer initiation vs promotion vs progression Why angiogenesis matters for tumors VEGF, VEGFR2, Akt, eNOS, nitric oxide, EGR-1, NAB2, and ERK The small human trial record The strongest concern-side evidence The strongest reassurance-side evidence Chapters: 00:00 Background 15:30 The Evidence Backdrop Bottom line: No evidence located that BPC-157 initiates cancer. A tumor-promotion concern remains biologically plausible but unproven. There is no long-term human cancer-safety dataset, no two-year carcinogenicity study, and no direct tumor-bearing animal program that answers the central question. This is educational content, not medical advice. If you have active cancer, prior cancer, a strong inherited cancer risk, an unexplained mass, or you are considering any unapproved peptide, talk with a clinician who knows your history. Sources and starting points: 1. The initial Jozwiak et al., 2025 Paper: https://doi.org/10.3390/ph18020185 2. Sikiric reply https://doi.org/10.3390/ph18101450 3. Jozwiak response to Sikiric's reply https://doi.org/10.3390/ph18101451 FDA - Certain Bulk Drug Substances for Compounding That May Present Significant Safety Risks: https://www.fda.gov/drugs/human-drug-... FDA PCAC meeting page for July 23-24, 2026: https://www.fda.gov/advisory-committe... WADA 2026 Prohibited List: https://www.wada-ama.org/sites/defaul... USADA on BPC-157: https://www.usada.org/spirit-of-sport... DoD OPSS on BPC-157: https://www.opss.org/article/bpc-157-... ClinicalTrials.gov records: NCT02637284 NCT07437547 Hsieh et al. 2017, VEGFR2/Akt/eNOS angiogenesis mechanism: PMID 27847966 Hsieh et al. 2020, Src-Caveolin-1-eNOS pathway: DOI 10.1038/s41598-020-74022-y Xu et al. 2020, preclinical safety evaluation: PMID 32334036 Radeljak, Seiwerth, Sikiric 2004, melanoma cell-line abstract: Melanoma Research 2004;14(4):A14-A15 Jozwiak et al. 2025 critique/reply: PMID 41155566 JMIR 2024 gray-market peptide quality analysis: PMC11582493 #bpc157 #peptides #cancerrisk #angiogenesis #evidencebasedmedicine